Cerebrolysin
clinical trialsAlso known as: FPF-1070
**Mechanism of Action** Cerebrolysin (FPF-1070) is a porcine brain-derived peptide preparation composed of low-molecular-weight neuropeptides and amino acids. Its mechanism mimics endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF). It promotes neuroprotection by reducing excitotoxicity, oxidative stress, and apoptosis, while enhancing neuroplasticity, synaptogenesis, and neurogenesis. Cerebrolysin also modulates amyloid precursor protein processing and attenuates tau hyperphosphorylation, contributing to its effects in neurodegenerative conditions. **Key Research Findings** Clinical trials have demonstrated efficacy in acute ischemic stroke, where Cerebrolysin improved functional outcomes (e.g., modified Rankin Scale) when administered within 24–72 hours, particularly in moderate-to-severe cases. In traumatic brain injury (TBI), meta-analyses suggest reduced mortality and improved cognitive recovery. For dementia (e.g., Alzheimer’s disease), randomized controlled trials show modest benefits in cognition and global function, especially when combined with cholinesterase inhibitors. However, heterogeneity in dosing, timing, and outcome measures limits consensus. Preclinical studies support its role in reducing infarct volume and enhancing synaptic plasticity. **Clinical Relevance** Cerebrolysin is approved in over 40 countries for stroke, TBI, and dementia, though not by the FDA. Its clinical utility is debated due to moderate effect sizes and variability in trial designs. Ongoing research aims to optimize patient selection (e.g., stroke subtype, dementia severity) and combination therapies. Safety profiles are generally favorable, with rare adverse events including injection-site reactions and transient dizziness. For research purposes only — not medical advice.
Key data
Research & studies
Post-stroke aphasia develops in about 30% of patients after a first stroke and is linked to greater cognitive deficits and increased vascular dementia risk.; Speech therapy is a primary treatment modality, and neuroplasticity is central to post-stroke recovery.; Cerebrolysin, a pleiotropic drug of neurotrophic peptides and free amino acids, can activate neuroplasticity.; The ESCAS study shows combined speech therapy and Cerebrolysin accelerates recovery of speech functions, supporting its use as an adjunct in rehabilitation.
Cerebrolysin group had higher rates of mRS 0-2 at 90 days (68% vs. 44%, p=0.016, NNT=4.2).; Secondary ICH risk was lower with Cerebrolysin (14% vs. 40%, p=0.02, RR 0.37).; Neurological recovery was faster, with lower NIHSS at day 7 (median 3 vs. 6, p=0.01).; Cerebrolysin was an independent predictor of favorable 3-month outcomes (OR 7.5), especially in diabetic patients (interaction OR 9.6).
Cerebrolysin has a relatively small potential application in psychiatry.; Limited evidence suggests it may support treatment of depression and autism spectrum disorders.; It may help alleviate adverse effects during neuroleptic treatment.; Data on cerebrolysin use in mental disorders are scarce in the literature.
Cerebrolysin group had a mean increase of 35.6 points on Western Aphasia Battery vs. 20.8 points in placebo (difference 14.8 points, P<0.001).; Cerebrolysin group showed greater reduction in NIHSS scores (difference 2.1 points, P<0.001).; Cerebrolysin group had greater improvements in functional independence (Barthel Index) and a trend toward reduced disability (modified Rankin Scale).; Adverse events did not differ significantly between groups (P=0.105 for number of patients, P=0.134 for events per patient).
Ginkgolide, edaravone, cinepazide maleate, citicoline, cerebrolysin, minocycline, and ginkgo diterpene lactone meglumine reduced mortality versus conventional treatment.; All drug regimens significantly improved neurological function, with citicoline + vinpocetine ranking highest.; Edaravone, ginkgolide, and edaravone dexborneol had the best balance of high treatment effectiveness and low adverse effects.; Edaravone, minocycline, edaravone dexborneol, ginkgo diterpene lactone meglumine, citicoline, and cerebrolysin had higher adverse effect rates than conventional treatment.
Severe anaphylaxis occurred after intravenous cerebrolysin in an 85-year-old stroke patient.; The reaction was confirmed by laboratory tests and successfully treated with prompt measures.; Only rare cases of cerebrolysin-induced anaphylaxis have been previously published.; The report highlights the need for awareness of unexpected anaphylactic reactions in critical patients using cerebrolysin.
Frequently asked questions
What is Cerebrolysin?
**Mechanism of Action** Cerebrolysin (FPF-1070) is a porcine brain-derived peptide preparation composed of low-molecular-weight neuropeptides and amino acids. Its mechanism mimics endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and
How does Cerebrolysin work?
Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.
What is the research status of Cerebrolysin?
Cerebrolysin is currently classified as clinical trials, with 639 research references on record. This is for research purposes only and is not medical advice.
Related peptides
CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.
33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.
NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.
ACTH(4-10)-derived heptapeptide that elevates BDNF and modulates the melanocortin system; used clinically in Russia for stroke and cognition.
Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.
Proline-containing dipeptide prodrug of cycloprolylglycine; increases BDNF/NGF expression with nootropic and anxiolytic effects.
Build on Cerebrolysin data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key